Abstract
BackgroundTofacitinib is an oral JAK inhibitor for the treatment of RA.ObjectivesThis analysis assessed if patients achieving Clinical Disease Activity Index (CDAI) remission (REM) or low disease activity (LDA) at Month...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
